Lifecare ASA (STO:LIFEO)
Sweden · Delayed Price · Currency is SEK · Price in NOK | Market Cap | 95.85M -49.7% |
| Revenue (ttm) | 7.25M -19.9% |
| Net Income | -132.99M |
| EPS | -0.45 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,400 |
| Open | 0.2825 |
| Previous Close | 0.2960 |
| Day's Range | 0.2825 - 0.2825 |
| 52-Week Range | 0.2825 - 18.1000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2026 |
About Lifecare ASA
Lifecare ASA, together with its subsidiaries, operates as a medical sensor company that develops technology for sensing and monitoring of various body analytes in Norway and United Kingdom. The company develops Sencell, a 3D printed nano-sensor for monitoring glucose levels in patients with diabetes and for veterinary applications; as well as medical devices that remove subdermal implants. Lifecare ASA was founded in 2006 and is headquartered in Bergen, Norway. [Read more]
Financial Performance
In 2025, Lifecare ASA's revenue was 6.64 million, a decrease of -31.34% compared to the previous year's 9.67 million. Losses were -119.51 million, 66.6% more than in 2024.
Financial numbers in NOK Financial StatementsNews
Lifecare ASA Earnings Call Transcript: Q1 2026
Q1 2026 marked a transformative quarter with key milestones in implant validation, regulatory progress, and operational restructuring. Significant cost reductions and capital raises improved financial stability, while the focus shifts to regulatory execution and scaling production.
Lifecare ASA Quarterly report: Q1 2026
Lifecare ASA has published its Q1 2026 quarterly earnings report on May 15, 2026.
Lifecare ASA Slides: Q1 2026
Lifecare ASA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 15, 2026.
Lifecare ASA Earnings Call Transcript: Q4 2025
Q4 2025 marked a shift from technology validation to operational execution, with regulatory milestones achieved and manufacturing reproducibility confirmed. Financially, short-term funding is secured, but future progress depends on warrant uptake and additional capital.
Lifecare ASA Annual report: Q4 2025
Lifecare ASA has published its Q4 2025 annual report on March 3, 2026.
Lifecare ASA Quarterly report: Q4 2025
Lifecare ASA has published its Q4 2025 quarterly earnings report on March 3, 2026.
Lifecare ASA Slides: Q4 2025
Lifecare ASA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 3, 2026.
Lifecare ASA Earnings Call Transcript: Q3 2025
Secured $80 million in funding and finalized product design, with a veterinary market launch targeted for early 2026 and a human CE mark and European launch expected in 2027. Q3 saw high operating expenses due to intensive product development and regulatory preparations.
Lifecare ASA Quarterly report: Q3 2025
Lifecare ASA has published its Q3 2025 quarterly earnings report on November 12, 2025.
Lifecare ASA Slides: Q3 2025
Lifecare ASA has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 12, 2025.
Lifecare ASA Earnings Call Transcript: Q2 2025
Development of implantable CGMs advanced with design freeze, clinical trial prep, and strategic partnerships. Q2 saw stable expenses, NOK 32M cash, and NOK 16M raised. Human and veterinary launches targeted for 2027 and 2025, with additional financing planned.
Lifecare ASA Quarterly report: Q2 2025
Lifecare ASA has published its Q2 2025 quarterly earnings report on August 20, 2025.
Lifecare ASA Slides: Q2 2025
Lifecare ASA has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 20, 2025.